The murine Fc-gamma (Fcγ) receptor type II B1 is a tumorigenicity-enhancing factor in polyoma-virus-transformed 3T3 cells
Open Access
- 17 January 1996
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 65 (2) , 221-229
- https://doi.org/10.1002/(sici)1097-0215(19960117)65:2<221::aid-ijc16>3.0.co;2-g
Abstract
The murine receptor for the Fc portion of IgG is a molecule expressed by cells of the immune system. This study suggests the hypothesis that Fcγ receptor type II B1 (FcγRIIB1) functions as a progression‐enhancing factor when expressed ectopically on non‐lymphoid tumor cells. It has been shown previously that BALB/c 3T3 cells transformed in vitro with polyoma virus (PyV) do not express FcγRII but acquire the expression of this receptor following an in vivo passage in syngeneic mice. The specific FcγRII transcript present in tumor cells was identified in this report as FcγRIIB1 (B1). In order to determine whether or not the ectopically expressed FcγRII plays a role in the progression of these transformed cells, PyV‐transformed 3T3 cells were transfected with B1‐cDNA. The B1 transfected cells were tested for their ability to form local tumors in syngeneic mice, as compared to transfected cells which express the co‐transfecting neomycine resistance (neores) DNA alone or together with the lacZ gene. FcγRIIB1 expressors exhibited a significantly higher tumorigenic phenotype than FcR‐negative controls, though both types of cells exhibited the same growth curve in vitro. The ability of FcγRIIB1 to act as a potentially tumorigenicity‐enhancing factor was also demonstrated as FcγRII was expressed by tumor cells, originating from inoculated FcγRIIB1‐transfected cells, or from inoculation of a mixture of receptor‐positive and ‐negative cells. B1‐expressing cells dominated the tumor‐cell population over non‐expressors. This dominance strengthened the hypothesis that FcR plays a role in tumor progression in vivo. © 1996 Wiley‐Liss, Inc.Keywords
This publication has 23 references indexed in Scilit:
- CD44 splice variants: metastases meet lymphocytesImmunology Today, 1993
- In vivo tumorigenicity and in vitro sensitivity to tumor-necrosis-factorα mediated killing of c-Ha-ras-transformed cellsCancer Immunology, Immunotherapy, 1992
- Cytoplasmic Domain Heterogeneity and Functions of IgG Fc Receptors in B LymphocytesScience, 1992
- Fc receptor endocytosis is controlled by a cytoplasmic domain determinant that actively prevents coated pit localization.The Journal of cell biology, 1992
- Fcγ Receptors are Expressed on Human Neuroblastoma Cell Lines: Lack of Correlation with N-Myc Oncogene ActivityInternational Journal of Neuroscience, 1991
- A genetic model for colorectal tumorigenesisCell, 1990
- Structural Heterogeneity and Functional Domains of Murine Immunoglobulin G Fc ReceptorsScience, 1986
- Fc and complement receptors on malignant tumor cellsCancer, 1981
- Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors.The Journal of Experimental Medicine, 1979
- Antibody-Mediated Hemadsorption by Tumor TissuesInternational Archives of Allergy and Immunology, 1968